[junkie-button url=”https://infomeddnews.com” style=”grey” size=”medium” type=”round” target=”_blank”] HOME [/junkie-button]
As part of the agreement, Cerveau will contract with the VUmc to manufacture and supply the [18F]MK-6240 needed for initiatives in the greater Amsterdam area.
According to Dr. Arjen Brussaard from VUmc “there is a large unmet need in the academic clinical setting, as well as with biotech and the pharmaceutical industry, to properly monitor and quantify the spread of tau pathology using positron emission tomography-PET. When Cerveau provided us the opportunity to work with the new tau imaging agent MK 6240 we eagerly pursued this opportunity since in many of the upcoming clinical trials in the field of Alzheimer’s Disease, the tau-opathy is becoming a primary outcome parameter given the fact that it correlates better with cognitive impairment in patients than for instance, beta-amyloid.”
“Cerveau welcomes this opportunity to work with the VUmc researchers to understand the application of MK-6240 and how it may benefit patients with this devastating disease. The collaboration with VUmc will provide access to our pharmaceutical partners in support of various therapy trials as well facilitate novel research at VUmc in the pursuit of evaluating potential preventive treatment options for Alzheimer’s disease,” said Rick Hiatt, President and CEO of Cerveau Technologies, Inc.